Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Thalidomide: a review of approved and investigational uses.
BACKGROUND Thalidomide is best known as a major teratogen that caused birth defects in up to 12,000 children in the 1960s. More recently, this agent has been approved by the US Food and Drug… Expand
Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019…
Importance Administration of hydroxychloroquine with or without azithromycin for the treatment of coronavirus disease 2019 (COVID-19)-associated pneumonia carries increased risk of corrected QT (QTc)… Expand
Peginterferon alfa-2a: a review of approved and investigational uses.
BACKGROUND In October 2002, the US Food and Drug Administration approved peginterferon alfa-2a for the management of chronic hepatitis C virus (HCV) infection. The addition of polyethylene glycol… Expand
Clinically Significant Adverse Events from a Drug Interaction Between Quetiapine and Atazanavir‐Ritonavir in Two Patients
Clinicians caring for patients infected with the human immunodeficiency virus (HIV) and diagnosed with psychiatric comorbidities must be aware of potential drug‐drug interactions, particularly with… Expand
Darunavir: a nonpeptidic antiretroviral protease inhibitor.
- Christopher M McCoy
- Clinical therapeutics
- 1 August 2007
BACKGROUND Protease inhibitors were a major therapeutic breakthrough in the mid-1990s for the treatment of HIV infection, which resulted in improved life expectancy for patients who had failed… Expand
Activity of fosfomycin and comparison of several susceptibility testing methods against contemporary urine isolates.
- Elizabeth B. Hirsch, Brian R. Raux, +5 authors G. Eliopoulos
- Biology, Medicine
- International journal of antimicrobial agents
- 1 December 2015
Fosfomycin is recommended as first-line treatment for acute uncomplicated cystitis in women. It has demonstrated in vitro activity against a variety of pathogens; however, a paucity of data are… Expand
Invitro Apramycin Activity against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa.
- A. D. Kang, Kenneth P. Smith, G. Eliopoulos, A. Berg, Christopher M McCoy, J. Kirby
- Biology, Medicine
- Diagnostic microbiology and infectious disease
- 1 June 2017
The in vitro activity of apramycin was compared to that of amikacin, gentamicin, and tobramycin against multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter baumannii… Expand
Bezlotoxumab: Could This be the Answer for Clostridium difficile Recurrence?
- R. Chapin, Tiffany Lee, Christopher M McCoy, C. D. Alonso, M. Mahoney
- The Annals of pharmacotherapy
- 6 May 2017
Objective: To review the pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of bezlotoxumab (BEZ), a novel monoclonal antibody against Clostridium difficile toxin B. Data Sources:… Expand
Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis.
BACKGROUND The search for a life-preserving drug to treat sepsis has increased understanding of the pathogenesis of the process but produced little in the way of successful treatments. The… Expand
Susceptibility of Multidrug-Resistant Gram-Negative Urine Isolates to Oral Antibiotics
- Elizabeth B. Hirsch, P. Zucchi, +4 authors G. Eliopoulos
- Antimicrobial Agents and Chemotherapy
- 16 February 2016
ABSTRACT Increasing resistance among Gram-negative uropathogens limits treatment options, and susceptibility data for multidrug-resistant isolates are limited. We assessed the activity of five oral… Expand